Your browser doesn't support javascript.
loading
Antiangiogenic antibody BD0801 combined with immune checkpoint inhibitors achieves synergistic antitumor activity and affects the tumor microenvironment.
Xue, Liting; Gao, Xingyuan; Zhang, Haoyu; Tang, Jianxing; Wang, Qian; Li, Feng; Li, Xinxin; Yu, Xiaohong; Lu, Zhihong; Huang, Yue; Tang, Renhong; Yang, Wenqing.
Afiliación
  • Xue L; State Key Laboratory of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Pharmaceutical Co. Ltd, Nanjing, Jiangsu, China.
  • Gao X; State Key Laboratory of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Pharmaceutical Co. Ltd, Nanjing, Jiangsu, China.
  • Zhang H; State Key Laboratory of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Pharmaceutical Co. Ltd, Nanjing, Jiangsu, China.
  • Tang J; State Key Laboratory of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Pharmaceutical Co. Ltd, Nanjing, Jiangsu, China.
  • Wang Q; State Key Laboratory of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Pharmaceutical Co. Ltd, Nanjing, Jiangsu, China.
  • Li F; DMPK and Clinical Pharmacology, Suzhou Ribo Life Science Co. Ltd, Kushan, Jiangsu, China.
  • Li X; State Key Laboratory of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Pharmaceutical Co. Ltd, Nanjing, Jiangsu, China.
  • Yu X; State Key Laboratory of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Pharmaceutical Co. Ltd, Nanjing, Jiangsu, China.
  • Lu Z; Green Valley Research Institute, Shanghai Green Valley Pharmaceutical Co., Ltd, Shanghai, China.
  • Huang Y; State Key Laboratory of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Pharmaceutical Co. Ltd, Nanjing, Jiangsu, China.
  • Tang R; State Key Laboratory of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Pharmaceutical Co. Ltd, Nanjing, Jiangsu, China.
  • Yang W; State Key Laboratory of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Pharmaceutical Co. Ltd, Nanjing, Jiangsu, China. wenqing.yang@cn.simcere.com.
BMC Cancer ; 21(1): 1134, 2021 Oct 22.
Article en En | MEDLINE | ID: mdl-34686154
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Inhibidores de la Angiogénesis / Inhibidores de Puntos de Control Inmunológico Tipo de estudio: Prognostic_studies Idioma: En Revista: BMC Cancer Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Inhibidores de la Angiogénesis / Inhibidores de Puntos de Control Inmunológico Tipo de estudio: Prognostic_studies Idioma: En Revista: BMC Cancer Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article